Antitumoral synergism between a copper(II) complex and cisplatin improves in vitro and in vivo anticancer activity against melanoma, lung and breast cancer cells

Mariani, Diana; Ghasemishahrestani, Zeinab; Freitas, William Rodrigues de; Pezzuto, Paula; Silva, Ana Caroline Costa da; Tanuri, Amílcar; Kanashiro, Milton; Fernandes, Christiane; Horn, Adolfo; Pereira, Marcos D.

doi:10.1016/j.bbagen.2021.129963

Cited by 17 publications

(14 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For B16 cells, when treated with (2), the cell viability decreased to 5%, with IC 50 values of 6.88 µg/mL (7.6 µM) after 24 h treatment and 4.15 µg/mL (4.58 µM) after 48 h, respectively (Table 3). The ligand dmtp did not affect the viability of either BJ or B16 cells at 24 or 48 h. It is worth mentioning that for other copper compounds tested on melanoma cells, the reported IC 50 values were similar [35][36][37][38][39][40][41][42][43], and only one study reported lower values [38] compared with those found for complex (1).…”

Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning

confidence: 94%

“…The Cu(II) systems represent beneficial species from this point of view, considering their reduced systemic toxicity [16]. Thus, several Cu(II) complexes were studied and proved to be as effective for melanoma treatment [18,29,[35][36][37][38][39][40][41][42][43]-some having, in addition, low toxicity on normal cells [18,29,[39][40][41][42][43].…”

Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning

confidence: 99%

“…Yield: 75% (0.34 g). Analysis, found: C, 43 The antimicrobial activity of the two complexes ( 1) and ( 2) was assessed using their minimum inhibitory concentration (MIC) by the broth microdilution method, as previously described by the Clinical and Laboratory Standard Institute (CLSI; M07-A9 document) [62]. A broth microdilution assay was performed in sterile 96-well plates using Muller-Hinton broth (Scharlau; MHB).…”

Section: Synthesis and Characterization Of The Complexesmentioning

confidence: 99%

See 2 more Smart Citations

Biological Activity of Triazolopyrimidine Copper(II) Complexes Modulated by an Auxiliary N-N-Chelating Heterocycle Ligands

et al. 2021

View full text Add to dashboard Cite

Novel complexes of type [Cu(N-N)(dmtp)2(OH2)](ClO4)2·dmtp ((1) N-N: 2,2′-bipyridine; (2) L: 1,10-phenantroline and dmtp: 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine) were designed in order to obtain biologically active compounds. Complexes were characterized as mononuclear species that crystallized in the space group P-1 of the triclinic system with a square pyramidal geometry around the copper (II). In addition to the antiproliferative effect on murine melanoma B16 cells, complex (1) exhibited low toxicity on normal BJ cells and did not affect membrane integrity. Complex (2) proved to be a more potent antimicrobial in comparison with (1), but both compounds were more active in comparison with dmtp—both against planktonic cells and biofilms. A stronger antimicrobial and antibiofilm effect was noticed against the Gram-positive strains, including methicillin-resistant Staphylococcus aureus (MRSA). Both electron paramagnetic resonance (EPR) and Saccharomyces cerevisiae studies indicated that the complexes were scavengers rather than reactive oxygen species promoters. Their DNA intercalating capacity was evidenced by modifications in both absorption and fluorescence spectra. Furthermore, both complexes exhibited nuclease-like activity, which increased in the presence of hydrogen peroxide.

show abstract

Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning

confidence: 94%

Section: Biological Characterization 231 Cell Viability and Lactate Dehydrogenase Assaysmentioning

confidence: 99%

Section: Synthesis and Characterization Of The Complexesmentioning

confidence: 99%

See 1 more Smart Citation

Biological Activity of Triazolopyrimidine Copper(II) Complexes Modulated by an Auxiliary N-N-Chelating Heterocycle Ligands

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Hence, in a continuous search for new antitumor drugs with reduced side effects and lower toxicity, the Cu(II) complexes are preferred, considering their reduced systemic toxicity [ 18 ]. Thus, several Cu(II) species were developed as non-toxic compounds for healthy tissue but with high activity in melanoma cells [ 33 , 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

Insights into Structure and Biological Activity of Copper(II) and Zinc(II) Complexes with Triazolopyrimidine Ligands

et al. 2022

View full text Add to dashboard Cite

In an attempt to increase the biological activity of the 1,2,4-triazolo[1,5-a]pyrimidine scaffold through complexation with essential metal ions, the complexes trans-[Cu(mptp)2Cl2] (1), [Zn(mptp)Cl2(DMSO)] (2) (mptp: 5-methyl-7-phenyl-1,2,4-triazolo[1,5-a]pyrimidine), [Cu2(dmtp)4Cl4]·2H2O (3) and [Zn(dmtp)2Cl2] (4) (dmtp: 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine), were synthesized and characterized as new antiproliferative and antimicrobial species. Both complexes (1) and (2) crystallize in the P21/n monoclinic space group, with the tetrahedral surroundings generating a square-planar stereochemistry in the Cu(II) complex and a tetrahedral stereochemistry in the Zn(II) species. The mononuclear units are interconnected in a supramolecular network through π–π interactions between the pyrimidine moiety and the phenyl ring in (1) while supramolecular chains resulting from C-H∙∙∙π interactions were observed in (2). All complexes exhibit an antiproliferative effect against B16 tumor cells and improved antibacterial and antifungal activities compared to the free ligands. Complex (3) displays the best antimicrobial activity against all four tested strains, both in the planktonic and biofilm-embedded states, which can be correlated to its stronger DNA-binding and nuclease-activity traits.

show abstract

“…2 Despite its high supply and demand as the first clinical anticancer drug, cisplatin has undeniable side effects such as pain, nausea, vomiting, neurotoxicity, nephrotoxicity, and hematological toxicity. [3][4][5][6] Generally, platinum-based compounds which act as soft nucleophiles play an essential role in cancer treatment via Pt-DNA interaction despite their side effects which limit their applications. In recent years, to overcome these limitations numerous strategies such as fluorination of certain bonds, using Pt(IV) instead of Pt(II) centers, multinuclear platinum complexes instead of ligands of mononuclear analogous and chelating nature were designed to optimize platinum-based drugs to approach more effective outcomes.…”

Section: Introductionmentioning

confidence: 99%

Binuclear platinum(ii) complexes bearing various bridging 1,1′-diphosphinoferrocene ligands as potential anticancer agents: synthesis and biological evaluation

et al. 2023

View full text Add to dashboard Cite

show abstract

Antitumoral synergism between a copper(II) complex and cisplatin improves in vitro and in vivo anticancer activity against melanoma, lung and breast cancer cells

Cited by 17 publications

References 65 publications

Biological Activity of Triazolopyrimidine Copper(II) Complexes Modulated by an Auxiliary N-N-Chelating Heterocycle Ligands

Biological Activity of Triazolopyrimidine Copper(II) Complexes Modulated by an Auxiliary N-N-Chelating Heterocycle Ligands

Insights into Structure and Biological Activity of Copper(II) and Zinc(II) Complexes with Triazolopyrimidine Ligands

Binuclear platinum(ii) complexes bearing various bridging 1,1′-diphosphinoferrocene ligands as potential anticancer agents: synthesis and biological evaluation

Contact Info

Product

Resources

About